西藏药业（600211）：公司事件点评报告：主营业务稳健，股权投资创新药打造新增长曲线

Investment Rating - The report maintains a "Buy" investment rating for the company [9] Core Views - The company's main business remains stable, with a slight revenue increase of 2.23% year-on-year, achieving revenue of 1.651 billion yuan in the first half of 2025. However, the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [1][2] - The company is focusing on investor returns by implementing a high cash dividend policy, distributing a total of approximately 631 million yuan in dividends in 2024, which accounts for 60% of the net profit attributable to shareholders [3] - The company is investing in innovative drug companies to create new growth curves, with a planned investment of 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake [4] Summary by Sections Main Business Performance - In the first half of 2025, the company achieved revenue of 1.651 billion yuan, with the main product, New Active Substance, selling 4.17 million units and generating revenue of 1.456 billion yuan, accounting for 88.36% of total revenue, a year-on-year increase of 0.41%. Other products generated revenue of 192 million yuan, a year-on-year increase of 18.83% [2] Cash Dividend Policy - The company has actively implemented stable cash dividend measures, with a proposed cash dividend of 8.81 yuan per 10 shares for the first half of 2025, which represents 50.05% of the net profit attributable to shareholders for that period [3] Investment in Innovative Drugs - The company announced an investment of 60 million USD in Accuredit Therapeutics Limited, acquiring a 40.82% stake. The core asset of Accuredit is Suzhou Rui Zheng Gene, which is the first company in China to enter clinical research for in vivo gene editing products based on LNP [4][8] Financial Forecast - The company is projected to achieve revenues of 2.923 billion yuan, 3.157 billion yuan, and 3.463 billion yuan for 2025, 2026, and 2027 respectively, with net profits of 893 million yuan, 967 million yuan, and 1.066 billion yuan for the same years [9][11]